Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform Thyroid epithelial cells in vivo

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3689-3694

  Miller, Kelly A ^a   Yeager, Nicole ^a   Baker, Kristen ^c   Liao, Xiao Hui ^b   Refetoff, Samuel ^b   Cristofano, Antonio D I ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENE DELETION; GENE MUTATION; GENE REPRESSION; INVASIVE CARCINOMA; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICLE CELL; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MAP KINASE SIGNALING SYSTEM; MICE; PROTO-ONCOGENE PROTEINS P21(RAS); THYROID GLAND; THYROID NEOPLASMS;

EID: 65949117244     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0024     Document Type: Article

References (28)

1. Shi YF, Zou MJ, Schmidt H. et al. High rates of ras codon 61 mutation in thyroid tumors in an iodidedeficient area. Cancer Res 1991; 51: 2690-3.
2. Vitagliano D, Portella G, Troncone G. et al. Thyroid targeting of the N-ras (Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 2006; 25: 5467-74 (Pubitemid 44330289)
3. Feunteun J, Michiels F, Rochefort P. et al. Targeted oncogenesis in the thyroid of transgenic mice. Horm Res 1997; 47: 137-9. (Pubitemid 27196445)
4. Tuveson DA, Shaw AT, Willis NA. et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-87. (Pubitemid 38482073)
5. Pandey J, Umphress SM, Rang Y. et al. Modulation of tumor induction and progression of oncogenic K-raspositive tumors in the presence of TGF- bl haploinsufficiency. Carcinogenesis 2007; 28: 2589-96. (Pubitemid 350238962)
6. Kirsch DG, Dinulescu DM, Miller JR. et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007; 13: 992-7. (Pubitemid 47222037)
7. Wang Y, Hou P, Yu H. et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 2007; 92: 2387-90. (Pubitemid 46997152)
8. Hou P, Liu D, Shan Y. et al. Genetic alterations and their relationship in the phosphatidylsositol 3-kinase /Akt pathway in thyroid cancer. Clin. Cancer Res 2007; 13: 1161-70. (Pubitemid 46424056)
9. Jackson EL, Willis M, Mercer K. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-8. (Pubitemid 34008190)
10. Kusakabe T, Kawaguehi A, Kawaguchi R, Feigenhaum L, Kimura S. Thyrocyte-speeifie expression of Cre recomhinase in transgenic mice. Genesis 2004; 39: 212-6. (Pubitemid 39079520)
11. Trotman LC, Mild M, Dotan ZA. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1: 385-96. (Pubitemid 39112137)
12. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J. Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: Strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid 1999; 9: 1265-71. (Pubitemid 30038940)
13. Hingorani SR, Petricoin Els Maitra A. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-50. (Pubitemid 38050041)
14. Haigis KM, Kendall KR, Wang Y. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-8.
15. Courtois-Cox S, Genther Williams SM, Reczek EE. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10: 459-72.
16. Macrae M, Neve RM, Rodriguez-Viciana P. et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8: 111-8. (Pubitemid 41132740)
17. Shaw AT, Meissner A, Dowdle JA. et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 2007; 21: 694-707. (Pubitemid 46440291)
18. Hou P, Ji M, Xing M. Association of pten gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008; 113: 2440-7.
19. Yeager K, Brewer C, Cai KQ, Xu XX, Di Cristofano A. inTOR is the key effector of P13K-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008; 68: 444-9.
20. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: Insights into thyroid function and Cowden disease pathogenesis. Cancer Res 2007; 67: 959-66. (Pubitemid 46270750)
21. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'- kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo, Mol. Cancer Ther. 2002; 1: 989-97.
22. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-13. (Pubitemid 46763015)
23. Iwanaga K, Yang Y, Raso MG. et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 2008; 68: 1119-27.
24. Lavoie JN, LAllemain G, Brunet A, Muller R, Pouyssegur J. Cyclin DI expression is regulated positively by the p42/p44MAPK and negatively by the p38 /HOGMAPK pathway. J. Biol. Chem 1996; 271: 20608-16. (Pubitemid 26281839)
25. Bellacosa A, Kumar C, Di Cristofano A, Testa JR Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Adv Cancer Res 2005; 94: 29-86. (Pubitemid 41202364)
26. Zafon C, Obiols G, Castellvi J, Ramon y Cajal S, Baena JA, Mesa J. Expression of p21cipl, p27kipl, and pl6INk4a cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: Correlation with clinicopathological factors. Endocr Pathol 2008; 19: 184-9.
27. Ferru A, Fromont G, Gibelin H. et al. The status of CDKN2A α (p16IKK4A) and β (pl4ARF) transcripts in thyroid tumour progression. Br J. Cancer 2006; 95: 1670-7.
28. Ball E, Bond J, Franc B, Demicco C, Wynford-Thomas D. An immunohistochemical study of pl6 (INK4a) expression in multistep thyroid tumourigenesis. Eur J. Cancer 2007; 43: 194-201. (Pubitemid 46054468)